Streetbeat News

Earnings

VZ

Verizon Communications (NYSE:VZ) has been the subject of diverse analyst opinions, with 9 analysts offering ratings ranging from bullish to bearish over the last three months. The average 12-month price target is $44.44, with a recent decrease of 1.68%. Analysts have adjusted their ratings and price targets, with some raising their targets and one lowering. Verizon's financials show a revenue decline of -2.64% for the quarter ending September 30, 2023, but strong net margin and ROE figures. The company's market cap is above industry average, indicating investor confidence.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 2:00 pm

DECK

Deckers Outdoor (NYSE:DECK) has been evaluated by 11 analysts in the past three months, with mixed sentiments. The average 12-month price target for DECK has risen 10.86% to $706.27. Analysts from firms including Piper Sandler, Wells Fargo, and Stifel have raised their price targets, reflecting positive views on the company's performance. Deckers Outdoor, known for brands like UGG and Teva, has shown strong financials with a 24.7% revenue growth rate, a net margin of 16.35%, and an ROE of 9.93%. The company's market capitalization is below the industry average, and it has a conservative debt-to-equity ratio of 0.14.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 2:00 pm

APA

In the last three months, 13 analysts have published diverse ratings on APA Corp (NASDAQ:APA), with an average 12-month price target of $44.08, down from $50.36. Analysts' actions include lowering and raising price targets and maintaining ratings. APA's financials show a revenue decline of -20.06% over 3 months, a high net margin of 19.89%, an ROE of 51.37%, and an ROA of 3.43%, but a high debt-to-equity ratio of 5.28.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 2:00 pm

MBRX

Moleculin Biotech, Inc. has released preliminary data from its Annamycin clinical trials, showing positive outcomes in treating acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The MB-106 AML trial has reached 67% recruitment with a CR rate of 40% and a CR/CRi rate of 47%. The first AML patient treated achieved a CR, and no CR/CRi patients have relapsed. The MB-107 STS Lung Mets trial reported a median overall survival of 11 months in heavily pre-treated subjects. All Annamycin subjects across multiple studies have shown no signs of cardiotoxicity. Moleculin anticipates multiple data readouts and a transition to pivotal Phase 2B/3 in 2024.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 1:58 pm

BTCS

BTCS Inc. (NASDAQ:BTCS), a blockchain technology company, issued a shareholder letter highlighting a successful 2023 with a 82% year-over-year increase in the fair market value of its crypto and cash to $26.7 million. The company anticipates over $6 million in net income for 2023, attributing this to the early adoption of new FASB accounting rules. BTCS plans to launch new Ethereum-based products and anticipates the introduction of an Ethereum ETF in 2024, although the timing is uncertain. The company also emphasized strategic cost-cutting and operational efficiency to navigate the challenging market.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 1:58 pm

SILO

Silo Pharma has announced positive results from a preclinical study showing the effectiveness of SPC-14 in combating stress, helplessness, and anxiety related to luteinizing hormone (LH) in Alzheimer's disease.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 1:55 pm

FMNB

Farmers National Banc (NASDAQ:FMNB) reported Q4 earnings with an EPS of $0.41, beating estimates by 17.14% against the expected $0.35. Revenue increased by $7.35 million compared to the same period last year. Historically, FMNB's share price increased by 2.79% the day after beating EPS estimates last quarter.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 1:55 pm

DAL

DHR

FLR

ILMN

RACE

Jim Cramer advised investors on CNBC's 'Mad Money Lightning Round' to avoid Delta Air Lines (DAL), citing that airlines should be considered trades, not long-term investments. Despite Delta's Q4 FY23 revenue growth, Cramer remains cautious. He also recommended staying away from Fluor Corporation (FLR) due to its inconsistent earnings history, with Q4 results expected on Feb. 20, 2024. Cramer labeled Illumina (ILMN) as 'second-rate' compared to Danaher Corporation (DHR) and suggested passing on Ferrari N.V. (RACE) despite its strong Q3 FY23 earnings. Stock movements were mixed, with DAL, FLR, and RACE experiencing gains, while DHR and ILMN saw modest changes.

Portfolio Pulse from Avi Kapoor

January 24, 2024 | 1:52 pm

NFLX

Netflix Inc (NASDAQ:NFLX) stock is rising after reporting Q4 financial results. Revenue increased 12.5% YoY to $8.83 billion, surpassing estimates of $8.72 billion. Earnings per share were $2.11, missing the $2.21 estimate. Paid net adds were 13.12 million, with total subscribers at 260.28 million, a 12.8% increase YoY. Netflix plans to expand its ad-supported tier and expects Q1 revenue of $9.24 billion and earnings of $4.49 per share, with a full-year 2024 operating margin target of 24%. Keybanc and Wedbush raised their price targets, while Deutsche Bank downgraded the stock but increased its price target.

Portfolio Pulse from Adam Eckert

January 24, 2024 | 1:51 pm

HTBI

HomeTrust Bancshares (NASDAQ:HTBI) reported Q2 2024 earnings of $0.79 per share, surpassing the consensus estimate of $0.71 by 11.27%.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 1:48 pm